“We are very confident that the 0.25 milligrams will be effective. We are confident that the effects on lymphocytes and CD4 T-cells will be comparable to any standard antiviral.”

In context

“Thank you. Dean Li: Thank you very much for that question. So, I just want to emphasize that islatravir is one molecule in our suite of NRTTI molecule. And as you mentioned, we are very interested in the importance of this body of molecules and mechanism, both for the prep setting and for the treatment setting. And it has the possibility of really transforming the longer-acting space. Specifically to your question, we have a large range of clinical data as many… Operator: We are sorry, your conference will end in one minute. Peter Dannenbaum: Excuse me, Dean. Leo, our conference will continue past 9:00 a.m. Operator: We are attempting to make sure that happens, sir. Peter Dannenbaum: Thank you. We are prepared to go a few extra minutes. Dean Li: And so we have a plethora of clinical data. We are very confident that the 0.25 milligrams will be effective. We are confident that the effects on lymphocytes and CD4 T-cells will be comparable to any standard antiviral. And so that’s in the Q day. We are also very interested in moving to the Q week with our partner, Gilead. And hopefully, that will begin to get posted more, but we are focusing on amending the protocol and the dosing regimen under the guidance of the FDA. And I also want to emphasize that we will continue to be committed on the two-month oral. I mean just think, 12 pills a year, 12 pills a year for patients who are high-risk take with PREP. We have MK-8527, it is a different molecule in our suite of NRTTIs. End of Q&A: Operator: We are sorry your conference is ending now. Please hang up. Peter Dannenbaum: Okay. So for those that are still on the line, thank you very much. We’ll have to close the call there because of those technical difficulties. For those that were in the queue, please f”